Esperion Therapeutics

Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor

Retrieved on: 
Martedì, Marzo 12, 2024
Professional Services, Health, Other Science, Finance, Research, Science, Biotechnology, RAPS, Eli Lilly, AstraZeneca, Ferris State University, Patient, Esperion Therapeutics, Sale, IPO, Pleasure, Esperies, Insys Therapeutics, Therapy, Investment, Multimedia, Pharmaceutical industry

Sofinnova Investments , a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor.

Key Points: 
  • Sofinnova Investments , a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor.
  • View the full release here: https://www.businesswire.com/news/home/20240312683597/en/
    Mr. Ignelzi brings to Sofinnova over two decades of financial leadership experience in the biotech and pharmaceuticals sectors.
  • Over the course of his career, Mr. Ignelzi has raised an impressive $4 billion-plus in capital for life science companies.
  • We are extremely pleased to have him join us,” said Jim Healy, M.D., Ph.D., Managing Partner, Sofinnova Investments.

RFK, Esperion Therapeutics Announce 2024 Promotional Schedule

Retrieved on: 
Giovedì, Febbraio 1, 2024
Partnership, Cholesterol, American College, Gout, Patient, Esperion Therapeutics, RFK Racing, RFK, American Heart Month, Allergy, NASCAR, Blood, Therapy, North Wilkesboro, North Carolina, Buescher, Ezetimibe, Pocono Raceway, Health, ACC, Uric acid, Pharmaceutical industry

CONCORD, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- RFK Racing and Esperion Therapeutics have announced the promotional schedule for the 2024 season, highlighted by a four-race slate, and numerous accompanying campaigns and initiatives, all driving awareness of its two brands – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid) used for adults on a statin to reduce LDL-cholesterol.

Key Points: 
  • CONCORD, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- RFK Racing and Esperion Therapeutics have announced the promotional schedule for the 2024 season, highlighted by a four-race slate, and numerous accompanying campaigns and initiatives, all driving awareness of its two brands – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid) used for adults on a statin to reduce LDL-cholesterol.
  • Brad Keselowski’s debut with the brand comes at the All-Star Race at North Wilkesboro (May 19).
  • In addition, Buescher will attend the annual American College of Cardiology (ACC) session on behalf of Esperion, in April in Atlanta.
  • “Our partnership thus far with RFK has proven to be very successful in many facets, and we’re excited to again embark on a new journey with the team in 2024,” said Sheldon Koenig, CEO, Esperion.

Care Access Becomes Newest Member of the National Lipid Association Industry Council, Joining Novartis, Amgen, and Other Cardiovascular Health Leaders

Retrieved on: 
Mercoledì, Gennaio 31, 2024
Research, Surgery, Clinical Trials, Cardiology, Practice Management, Other Health, Health, General Health, Science, Principal, Stenosis, Physician, Novartis, National Lipid Association, Regeneron Pharmaceuticals, Clinical trial, Access, Cardiovascular disease, Patient, Esperion Therapeutics, Entrepreneurship, Therapy, Risk, NLA, Coronary artery disease, Learning, Stroke, Medicine, Amgen, Esperies, JD, Pharmaceutical industry

Care Access, a global clinical research company helping to accelerate the future of medicine, is joining the National Lipid Association (NLA) Industry Council.

Key Points: 
  • Care Access, a global clinical research company helping to accelerate the future of medicine, is joining the National Lipid Association (NLA) Industry Council.
  • The collaboration aims to enable more community-based lipidologists to participate in clinical research and create access to cardiometabolic trials for their patients.
  • The NLA represents doctors and other experts from around the country who treat patients at the highest risks of cardiovascular disease.
  • "At Care Access, we are committed to facilitating clinical trial access for patients from all walks of life," said Ahmad Namvargolian, Care Access CEO and Co-Founder.

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

Retrieved on: 
Mercoledì, Gennaio 3, 2024
Science, Cardiology, Other Science, Research, Pharmaceutical, Oncology, General Health, Health, Partnership, Tablet, Disability, EMA, ESPR, Esperion Therapeutics, Bempedoic acid, Therapy, Death, Calendar, European Medicines Agency, Patient, Cardiovascular disease, Ezetimibe, District court, Pharmaceutical industry

DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application.

Key Points: 
  • DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application.
  • The legal action pending in the United States District Court for the Southern District of New York will be dismissed.
  • Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the eligible patient population and unlock its potential for cardiovascular risk reduction.
  • The partnership continues to grow, with DSE recently gaining approvals for bempedoic acid in the Netherlands, Slovakia, and Spain.

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

Retrieved on: 
Mercoledì, Gennaio 3, 2024
Partnership, Tablet, Disability, EMA, ESPR, Esperion Therapeutics, Bempedoic acid, Therapy, Death, Calendar, ANN, European Medicines Agency, Patient, Cardiovascular disease, Ezetimibe, District court, Pharmaceutical industry

ANN ARBOR, Mich. and MUNICH, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE), the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (TSE: 4568), announced today a $125 million amendment to their collaboration, which includes an amicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products.

Key Points: 
  • DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application.
  • The legal action pending in the United States District Court for the Southern District of New York will be dismissed.
  • Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the eligible patient population and unlock its potential for cardiovascular risk reduction.
  • The partnership continues to grow, with DSE recently gaining approvals for bempedoic acid in the Netherlands, Slovakia, and Spain.

U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

Retrieved on: 
Mercoledì, Dicembre 13, 2023
PDUFA date, Constipation, Risk, Tendon rupture, Moyamoya disease, FDA, Fatigue, Health, Bempedoic acid, Fetus, Back pain, Agent handling, Sinusitis, Pain, PDUFA, Diet, Uric acid, CLEAR, ATP, Safety, Kidney, Bronchitis, Food, Pregnancy, Mortality, Angioedema, Therapy, CVD, ANN, Esperies, Tablet, Patient, Ezetimibe, Spasm, Anaphylaxis, Upper respiratory tract infection, Diarrhea, Anemia, Disease, ESPR, Rupture, Incidence, Abdominal pain, Urinary tract infection, Gout, Hypersensitivity, Use, Esperion Therapeutics, Arthralgia, Rash, Pharmaceutical industry

ANN ARBOR, Mich., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Food and Drug Administration (FDA) has approved an updated LDL-cholesterol lowering indication for NEXLETOL and NEXLIZET to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations. Additionally, the maximally tolerated qualifier for statin use has been removed, and the prior limitation of use stating “the effect of NEXLIZET or NEXLETOL on cardiovascular morbidity and mortality has not been determined” has also been removed.

Key Points: 
  • These applications were accepted by the FDA which issued a PDUFA, or action, date of March 31, 2024.
  • The Company’s EMA applications also remain on track, with anticipated approval in the first half of 2024.
  • Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels which may lead to gout.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

Retrieved on: 
Lunedì, Novembre 13, 2023
Disease, Esperion Therapeutics, Rash, Abdominal pain, AHA, Membrane protein, Patient, Bempedoic acid, PCSK9, CVD, Anemia, Angioedema, Rupture, Inflammation, Diet, Atherosclerosis, Safety, Incidence, FAHA, Mortality, Tablet, Health, Tendon rupture, Diarrhea, Harvard Medical School, Ezetimibe, Urinary tract infection, Fetus, Hypersensitivity, Arthralgia, Gout, American Heart Association, ESPR, Therapy, Sinusitis, Risk, Spasm, Constipation, MACE, Anaphylaxis, Pain, Moyamoya disease, Back pain, Upper respiratory tract infection, FACC, Flexner Report, CLEAR, Fatigue, Pregnancy, Kidney, Uric acid, MPH, ATP, Bronchitis, Hospital, Dietary supplement, Pharmaceutical industry, Vaccine, Common, Esperies, Brigham, Hyperuricemia, MD, Cholesterol

ANN ARBOR, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. Results were also simultaneously published in Circulation which can be accessed here.

Key Points: 
  • “In the future, it can be anticipated that virtually all atherosclerosis patients will receive aggressive inflammation inhibition along with aggressive cholesterol reduction,” Ridker added.
  • In CLEAR Outcomes, patients who were randomized to bempedoic acid experienced a 21.6% reduction in hsCRP compared to placebo at 6 months.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Cleerly, Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023

Retrieved on: 
Sabato, Novembre 11, 2023
Health, Technology, Health Technology, Clinical Trials, Artificial Intelligence, Pharmaceutical, Cardiology, Esperion Therapeutics, Participation, Ezetimibe, Atherosclerosis, Therapy, FAHA, Plaque, FACC, AHA, Cholesterol, Risk, CCTA, Cardiovascular disease, CAD, Tablet, Patient, Myocardial infarction, Bempedoic acid, Molina Healthcare, LDL, Type 2 diabetes, American Heart Association, University, Diagnosis, Pulmonary Vascular Research Institute, MPH, FESC, Splenic infarction, ASCVD, AI, Metabolic syndrome, Prediabetes, American Heart, Moyamoya disease, Pharmaceutical industry, Dietary supplement, Management, Medical imaging, Medicine, MD

Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions.

Key Points: 
  • Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions.
  • TRANSFORM is a randomized trial – sponsored by Cleerly – that aims to enroll 7,500 patients who have pre-diabetes, type 2 diabetes, or metabolic syndrome and have no symptoms of heart disease.
  • TRANSFORM aims to prove that a personalized care strategy based on a Cleerly analysis is better than usual care based on traditional cardiovascular risk factors for the primary prevention of cardiovascular events.
  • “This trial provides us the opportunity to revolutionize cardiovascular event prevention and ultimately save lives from heart disease.

BioFlorida Appoints Mark A. Glickman as President & CEO to Continue to Propel Florida's Life Sciences Community Forward

Retrieved on: 
Lunedì, Dicembre 4, 2023
Auxilium, Esperion Therapeutics, Sale, Principal, Esperies, Negotiation, Research, Therapy, Patient, MBA, Retirement, PALM, Growth, Hospira, Human, Management, Fine chemical, Capitol

WEST PALM BEACH, Fla., Dec. 4, 2023 /PRNewswire/ -- BioFlorida, the leading voice of Florida's life sciences industry, announced that Mark A. Glickman, MBA, will serve as its new President and Chief Executive Officer.

Key Points: 
  • WEST PALM BEACH, Fla., Dec. 4, 2023 /PRNewswire/ -- BioFlorida, the leading voice of Florida's life sciences industry, announced that Mark A. Glickman, MBA, will serve as its new President and Chief Executive Officer.
  • A longstanding member of Florida's life sciences community, Mr. Glickman brings over 30 years of experience and leadership to BioFlorida.
  • "We are thrilled to welcome Mark Glickman as BioFlorida's new President and CEO," said Robert Finizio, Chairman of the Board for BioFlorida.
  • Mark Glickman will officially assume the role of President and CEO of BioFlorida on December 9, 2023.

Rapport Therapeutics Appoints Chief Financial Officer

Retrieved on: 
Lunedì, Ottobre 30, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Science, IPO, Sale, AstraZeneca, Abivax, RAPS, Esperion Therapeutics, Eli Lilly, Esperies, Insys Therapeutics, Multimedia, DSM-IV codes, Ferris State University, Therapy, Patient, Pharmaceutical industry, Rapport

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231030359557/en/
    “We are thrilled to welcome Troy to the Rapport executive team during this time of rapid progress for our company,” said Abraham Ceesay, Chief Executive Officer of Rapport.
  • Most recently, he was Chief Financial Officer at Karuna Therapeutics, where he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings.
  • Prior to Karuna, Mr. Ignelzi served as Chief Financial Officer at two other companies, Juventas Therapeutics and scPharmaceuticals.